UPCC 11222: A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
Enrolling By Invitation
99 years and younger
All
1 Location
Brief description of study
The purpose of this study is to test the safety and effectiveness of domvanalimab when given together with zimberelimab with and without chemotherapy.
We would like to rely on WCG the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
08 Feb 2023.
Study ID: 851766
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
